Health

ImmunOs Therapeutics

Private Company

ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases. The Company┬┤s lead product candidate has the potential to treat multiple types of solid tumors and hematologic malignancies by targeting multiple components of the immune system to activate profound anti-tumor responses. ImmunOs is also developing antibodies to block the activation of specific HLA protein molecules associated with autoimmune diseases.

immunostherapeutics.com

U.S.

Europe

Leaders
Sean R. Smith

CEO

Lightspeed Team

ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases. The Company┬┤s lead product candidate has the potential to treat multiple types of solid tumors and hematologic malignancies by targeting multiple components of the immune system to activate profound anti-tumor responses. ImmunOs is also developing antibodies to block the activation of specific HLA protein molecules associated with autoimmune diseases.